Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.
View Top Employees from Inventiva Pharma| Website | http://www.inventivapharma.com |
| Ticker | IVA |
| Revenue | $11 million |
| Funding | $124.1 million |
| Employees | 117 (90 on RocketReach) |
| Founded | 2012 |
| Address | 50 Rue De Dijon, Daix, Bourgogne-Franche-Comte 21121, FR |
| Phone | +33 3 80 44 75 00 |
| Technologies |
JavaScript,
HTML,
Twitter
+15 more
(view full list)
|
| Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Drug Discovery, Healthcare, Biotechnology, Health Care, Science and Engineering, Clinical Trials, Medical, Medical Device |
| Web Rank | 4 Million |
| Keywords | Oncology, Biopharmaceuticals, Small Molecule Drug Discovery, Unmet Medical Needs |
| Competitors | Galecto, Inc., Idera Pharmaceuticals, Lumos Pharma, Phenex Pharmaceuticals AG, Trevena Inc |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Inventiva Pharma employee's phone or email?
Inventiva Pharma Questions
The Inventiva Pharma annual revenue was $11 million in 2024.
Michael Cooreman is the Chief Medical Officer of Inventiva Pharma.
90 people are employed at Inventiva Pharma.
Inventiva Pharma is based in Daix, Bourgogne-Franche-Comte.
The NAICS codes for Inventiva Pharma are [32541, 32, 325, 3254].
The SIC codes for Inventiva Pharma are [283, 28].
Top Inventiva Pharma Employees
-
44
-
3
-
5+5+
-
ViewLouis Griffel
Vice President Clinical Development at Inventiva Pharma
New York, New York, United States5+5+ -
5+3
-
41
-
2
-
35+
